Showing results (151-160 of 166) with videos related to
Sort By:
Pageof 17
Cancer Causes & Control : CCC|July 14, 2019
Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohortJop C Teepen, Leontien C Kremer, Margriet van der Heiden-van der Loo, et al.European Journal of Cancer (Oxford, England : 1990)|October 8, 2022
Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysisFrederik O Meeuwes, Mirian Brink, Marjolein W M van der Poel, et al.European Journal of Cancer (Oxford, England : 1990)|March 8, 2025
Long-term survival for myeloid neoplasms and national health expenditure: A EUROCARE-6 retrospective, population-based studyClaudia Vener, Roberto Lillini, Roberta De Angelis, et al.Cancer Medicine|December 29, 2018
Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancerLisanne S Rigter, Michael Schaapveld, Cecile P M Janus, et al.Annals of Hematology|October 4, 2024
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcomeGerwin Huls, Dana A Chitu, Lidwine Tick, et al.Haematologica|October 5, 2023
Outcome of combined modality treatment in first-line for stage I(E) peripheral T-cell lymphoma; a nationwide population-based cohort study from the NetherlandsFrederik O Meeuwes, Mirian Brink, Wouter Plattel, et al.Lancet (London, England)|February 4, 2018
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesClaudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2017
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of ChemotherapyJop C Teepen, Flora E van Leeuwen, Wim J Tissing, et al.The New England Journal of Medicine|December 25, 2015
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's LymphomaMichael Schaapveld, Berthe M P Aleman, Anna M van Eggermond, et al.BMJ Oncology|January 31, 2025
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?Z L Rana Kaplan, Nikki van Leeuwen, David van Klaveren, et al.Pageof 17